Preview this report's Table of Contents.
Get the latest information and unique perspectives on where diagnostic testing
is headed, with comprehensive coverage of every innovation, new product, manufacturer,
market and end-user application.
Compiled by the publishers of Diagnostic Testing & Technology Report
newsletter, this one-of-a-kind resource will help you stay abreast of the
developments in such critical areas as Biomarkers, Infectious Diseases, Pharmacogenomics
and Molecular Testing.
Review vital data for the year and prepare your game plan for the long term
by learning how labs are using new tools and the science behind the tests.
With insight and opinions drawn from top experts in the field, as well as numerous
other resources, this Washington G-2 research report includes:
- Developments in key areas like infectious diseases, cancer diagnostics,
and molecular diagnostics
- Risk of esophageal cancer tied to gene variants
- Study finds oral fluid drug test results comparable to urine testing
- Tumor database to combine microscopy, microarray information
- Biomarkers show promise for early diagnosis of Alzheimer’s disease
- and much more
- Reports on patents, approvals, and laws and regulations
- FDA okays first rapid blood test for drug-resistant staph
- CMS to delay anti-markup provisions for diagnostic tests
- FDA clears real-time PCR assay for respiratory viruses
- FDA licenses Olumpus blood-typing tests, clears Instrument System
- And much more
- Analysis of test trends and markets
- Protein-based blood test could predict impending heart attack
- Risk of esophageal cancer tied to gene variants
- Study finds oral fluid drug test tesults comparable to urine testing
- Tumor database to combine microscopy, Microarray Information
- As rising costs threaten future of cancer care, OncotypeDX
- Found to influence treatment decisions
- Discoverers of HPV, HIV Win Nobel Prize
- Gene variant linked to liver disease
- And much more
- New tests labs are adding to their menus
- FDA clears Pathwork Diagnostics tumor origin test
- FDA clears Invitrogen’s CISH test for HER2
- CMS adds more waived tests to Lab Fee Schedule
- Nanogen to develop flu test for CDC
- FDA clears Thermo Fisher’s MRSA test
- FDA approves Dako’s TOP2A gene test for breast cancer patients
- And Much More
- Detailed reviews of the mergers within the last 12 months, acquisitions
and firm strategies
- Sequenom to acquire center for molecular medicine
- Molecular diagnostics is largest growth area at Alverno Clinical Labs
- Pathwork Diagnostics raises $20 Million
- Pall Corporation acquires GeneSystems
- Innovative Biosensors raises $11.5 Million
- Manhattan Physicians Laboratory buys Genatom Labs
- And much more
